Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 304 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No Investigational Product Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Intranasal Heparin Tolerability Study

NCT04490239
View directory record Official record
Conditions
Covid19
Interventions
Intranasal heparin sodium (porcine)
Drug
Lead sponsor
Joshua Sharp
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

NCT01527500
View directory record Official record
Conditions
Geographic Atrophy, Age-related Macular Degeneration
Interventions
LFG316, Sham, LFG316 Lower dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 30, 2026, 8:32 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate Effects of an Oral Rinse on Plaque and Gingivitis

NCT03421145
View directory record Official record
Conditions
Plaque
Interventions
3M™ Oral Rinse, Vehicle Control Oral Rinse, PerioShield™ Oral Health Rinse, Water
Device · Other
Lead sponsor
Solventum US LLC
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

NCT00867152
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Darunavir, Etravirine, Ritonavir, Lopinavir/ritonavir, GSK1349572
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Sep 30, 2026, 8:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Green Light Effect on Sleep

NCT04828473
View directory record Official record
Conditions
Sleep
Interventions
Allay Lamp
Device
Lead sponsor
The Green Light Study Center
Other
Eligibility
40 Years to 95 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

NCT03307577
View directory record Official record
Conditions
Acne Vulgaris
Interventions
UHE-101 Cream, Vehicle Cream
Drug · Other
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Sep 30, 2026, 8:32 AM EDT
Not listed Not applicable Interventional

Green Light Effects on Anxiety

NCT04871087
View directory record Official record
Conditions
Anxiety
Interventions
Green Light
Device
Lead sponsor
The Green Light Study Center
Other
Eligibility
18 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Main Study: A Study to Evaluate the Effectiveness and Safety of GAL1906 for Correction of Wrinkles in the décolletage Area Sub-study: A Follow-up Study to Evaluate the Analysis of Mammograms Following Treatment for Correction of Wrinkles in Décolletage Area in the Investigational Study 43USRV1906

NCT04717934
View directory record Official record
Conditions
Wrinkle
Interventions
GAL1906
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older · Female only
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redondo Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

NCT02284568
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Placebo, Laquinimod
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 30, 2026, 8:32 AM EDT
Active, not recruiting Phase 2 Interventional

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Dasatinib + Quercetin, Placebo Capsules
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 30, 2026, 8:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strengthening Circadian Signals

NCT03490864
View directory record Official record
Conditions
Improving Cardiometabolic Outcomes in Adults
Interventions
Melatonin 1 mg, Placebos, Meal Timing, NON Meal Timing
Dietary Supplement · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 54 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Sep 30, 2026, 8:32 AM EDT
Active, not recruiting Phase 3 Interventional

TARGET BP I Clinical Trial

NCT02910414
View directory record Official record
Conditions
Hypertension
Interventions
Dehydrated alcohol, Peregrine System Kit (Sham Procedure)
Drug · Device
Lead sponsor
Ablative Solutions, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

NCT03883919
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 30, 2026, 8:32 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older

NCT03074266
View directory record Official record
Conditions
Blood Coagulation Test
Interventions
GEM Hemochron 100 ACT
Diagnostic Test
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Nitrous Oxide Neuroimaging

NCT06702631
View directory record Official record
Conditions
Anesthesia, Pain, Amnesia
Interventions
Nitrous oxide, Peripheral Nerve Stimulation
Drug · Device
Lead sponsor
Keith M Vogt
Other
Eligibility
18 Years to 59 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 8:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function

NCT06776081
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Weight loss without pharmacotherapy
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
40 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 30, 2026, 8:32 AM EDT
Recruiting Phase 1 Interventional

Mitigating the Pro-inflammatory Phenotype of Obesity

NCT04934228
View directory record Official record
Conditions
Blood Pressure, Diabetes, Obesity, Insulin Resistance, Diuretics Drug Reactions, Sympathetic Nerve Activity
Interventions
Hydrochlorothiazide 12.5Mg Tab, Clonidine Pill, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 30, 2026, 8:32 AM EDT
Completed No phase listed Observational

Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients

NCT06500741
View directory record Official record
Conditions
Prostate Cancer
Interventions
No Intervention
Other
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene

NCT03780257
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
QR-421a, Sham-procedure (dose cohort 1&2 only)
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Not applicable Interventional

A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

NCT04740892
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Wash IP, Cream IP
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
3 Months to 72 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
High Point, North Carolina • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 30, 2026, 8:32 AM EDT
Enrolling by invitation No phase listed Observational

Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T

NCT05529342
View directory record Official record
Conditions
HIV
Interventions
Gene modified therapy
Biological
Lead sponsor
American Gene Technologies International Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 1 Interventional

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

NCT03467789
View directory record Official record
Conditions
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions
Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 30, 2026, 8:32 AM EDT
Completed Phase 2 Interventional

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

NCT01778218
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose
Radiation
Lead sponsor
Cell>Point LLC
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Sep 30, 2026, 8:32 AM EDT